SHANDONG BOAN BIOTECH.H 1 Total Liabilities
SHANDONG BOAN BIOTECH.H 1 total liabilities. Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) has total liabilities worth €1.39 Billion EUR (≈ $1.62 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SHANDONG BOAN BIOTECH.H 1 liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SHANDONG BOAN BIOTECH.H 1 (2021–2025)
Total liabilities of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025. This chart illustrates how SHANDONG BOAN BIOTECH.H 1's total liabilities have evolved over time, based on quarterly financial data.
SHANDONG BOAN BIOTECH.H 1 Competitors by Total Liabilities
The table below lists competitors of SHANDONG BOAN BIOTECH.H 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caisse régionale de Crédit Agricole Mutuel d-Ille-et-Vilaine SC
PA:CIV
|
France | €18.62 Billion |
|
MAKUS Inc
KQ:093520
|
Korea | ₩138.88 Billion |
|
Zhejiang Linuo Flow Control Techno
SHE:300838
|
China | CN¥935.96 Million |
|
Kerur Holdings Ltd
TA:KRUR
|
Israel | ILA256.32 Million |
|
Jiangsu Gaoke Petrochemical Co
SHE:002778
|
China | CN¥174.29 Million |
|
Genfit S.A.
NASDAQ:GNFT
|
USA | $164.21 Million |
|
Com2uS Corporation
KQ:078340
|
Korea | ₩501.87 Billion |
|
Zippy Technology Corp
TW:2420
|
Taiwan | NT$1.69 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANDONG BOAN BIOTECH.H 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of SHANDONG BOAN BIOTECH.H 1.
Liquidity & Leverage Metrics
SHANDONG BOAN BIOTECH.H 1 Total Liabilities Ratios Explained
SHANDONG BOAN BIOTECH.H 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANDONG BOAN BIOTECH.H 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANDONG BOAN BIOTECH.H 1 (2021–2025)
The table below shows the annual total liabilities of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.39 Billion ≈ $1.62 Billion |
+14.79% |
| 2024-12-31 | €1.21 Billion ≈ $1.41 Billion |
+20.30% |
| 2023-12-31 | €1.00 Billion ≈ $1.17 Billion |
+27.97% |
| 2022-12-31 | €784.18 Million ≈ $916.79 Million |
+41.32% |
| 2021-12-31 | €554.92 Million ≈ $648.76 Million |
-- |
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more